How Early Diagnosis and Copper Chelation Kept a Young Wilson Disease Patient on Track
Patient Profile
Field | Details |
Age | 19 years |
Gender | Male |
Occupation | College student |
City | Pune |
Presenting Complaint | Persistent fatigue, mild jaundice, and a decline in academic performance noticed by family over several months |
Diagnosis | Wilson disease with hepatic involvement, confirmed on biochemical and genetic testing |
Duration of Issue | Symptoms present for approximately six months before diagnosis |
Previous Treatments | None, condition was previously undiagnosed and attributed to academic stress |
Date of Procedure | January 2026, managed on an ongoing outpatient basis |
Outcome | Excellent, liver function stabilised and patient remains on structured long term chelation |
The Problem
Condition
Wilson disease is a rare autosomal recessive genetic disorder in which the body is unable to excrete copper normally, leading to progressive accumulation of the metal in the liver, brain, and other organs. This patient presented with unexplained fatigue, mildly elevated liver enzymes, and subtle yellowing of the eyes that had been dismissed as study related stress for several months before a blood test prompted further investigation. Serum ceruloplasmin was found to be significantly low, urinary copper excretion was elevated on a twenty four hour collection, and a slit lamp examination confirmed the presence of Kayser Fleischer rings, the characteristic golden brown corneal deposits caused by copper accumulation. The diagnosis placed this patient firmly in the category requiring prompt liver cirrhosis treatment evaluation, since unmanaged Wilson disease can progress rapidly to cirrhosis and liver failure in young patients if the underlying copper load is not addressed early.
Emotional & Psychological Impact
For a nineteen year old in the middle of competitive college exams, the diagnosis of a lifelong genetic liver condition came as a significant shock. His family had assumed the fatigue and mild confusion episodes were consequences of long study hours and poor sleep, not signs of organ level copper toxicity. Learning that the condition was inherited and would require lifelong medication was initially difficult for both the patient and his parents to accept. He had also been experiencing subtle mood changes and difficulty concentrating over the preceding months, symptoms that are consistent with early neurological copper deposition and are often misread in young adults as anxiety or stress. Reading more about the condition brought him to a page similar to this resource on hepatitis and liver disease, which helped his family understand how early intervention in liver conditions can substantially alter long term outcomes.
Consultation & Treatment Plan
What Was Assessed During the Consultation?
- Serum ceruloplasmin, serum copper, and twenty four hour urinary copper to confirm the diagnosis biochemically
- Slit lamp eye examination to identify Kayser Fleischer rings
- Liver function tests, complete blood count, and coagulation profile to assess current hepatic reserve
- Abdominal ultrasound and liver elastography to evaluate the degree of fibrosis present at the time of diagnosis
- ATP7B genetic testing to confirm the mutation and allow family screening of first degree relatives
- Neurological and psychiatric baseline assessment to rule out early central nervous system involvement
Why This Chelation Led Approach Was Chosen
Dr. Kothari selected D penicillamine based copper chelation as the first line treatment, with a structured titration plan and close monitoring for side effects. The reasoning behind this approach included the following points.
- Chelation therapy remains the most effective way to increase urinary copper excretion in newly diagnosed symptomatic patients, directly reducing the toxic copper burden in the liver
- Starting at a lower dose and increasing gradually was chosen to minimise the risk of early neurological worsening, a recognised complication when chelation mobilises copper rapidly at the outset of treatment
- Zinc supplementation was planned as a maintenance adjunct once initial copper depletion was achieved, to block ongoing intestinal copper absorption without the side effect profile of long term chelation alone
- Genetic confirmation and family screening were prioritised to identify any siblings or parents who might be presymptomatic carriers requiring their own monitoring
Baseline Assessment & Documentation
Baseline biochemical, imaging, and genetic documentation was completed at the first consultation before any treatment began. This fixed an objective starting point for tracking copper reduction, liver function improvement, and elastography changes across follow up visits.
Management Protocol:- Step by Step
- Full diagnostic workup completed at first presentation, including slit lamp examination, urinary copper, ceruloplasmin, and genetic testing
- D penicillamine chelation commenced at a low starting dose with gradual titration over the first four weeks
- Dietary guidance provided to reduce high copper foods such as shellfish, nuts, and chocolate during the active copper depletion phase
- Monthly blood and urine monitoring introduced to check for medication side effects including haematological changes and proteinuria
- Liver stiffness tracked by periodic FibroScan to confirm that fibrosis was not progressing under treatment
- Zinc acetate introduced as a planned maintenance agent once urinary copper normalised, to be used alongside chelation for long term copper balance
- Siblings referred for ceruloplasmin and urinary copper screening to detect presymptomatic disease in the family
Management Facts
| Field | Details |
| Setting | Outpatient, no hospital admission required |
| Anaesthesia | None required |
| Key Diagnostic Tool | Serum ceruloplasmin, 24 hour urinary copper, slit lamp examination, ATP7B genetic test |
| Treatment Approach | D penicillamine chelation with gradual titration, dietary copper restriction, and planned zinc maintenance |
| Complications | None observed during initial titration phase |
| Review Frequency | Monthly for the first six months, then every three months |
Post Management Results
Within three months of starting chelation, liver enzyme levels showed a clear downward trend and the patient reported noticeable improvement in energy levels and concentration. Urinary copper output, initially very high, began normalising by month four, confirming that the chelation protocol was working as intended. Repeat elastography at six months confirmed no progression of liver stiffness from the baseline measurement, and the patient’s mood and cognitive symptoms had largely resolved. The patient and his family reported a meaningful improvement in day to day functioning, and he was able to return to his academic schedule without significant difficulty.
Outcomes at a Glance
| Outcome Metric | Result |
| Liver Enzyme Trend | Normalising progressively from month three |
| Urinary Copper Output | Significantly reduced by month four |
| Liver Stiffness | Stable, no progression confirmed on elastography |
| Neurological Symptoms | Resolved within the first few months of treatment |
| Patient Satisfaction | Very high, returned to normal academic and daily functioning |
Ongoing Care & Maintenance
Instructions Given to Patient
- Continue chelation medication consistently at the prescribed dose, without skipping doses, since interruption can cause rapid copper reaccumulation
- Maintain a low copper diet throughout, avoiding shellfish, organ meats, nuts, chocolate, and mushrooms in large quantities
- Never take copper containing multivitamin supplements
- Attend all scheduled blood, urine, and imaging reviews without delay
- Report any new tremors, speech changes, or worsening mood promptly, as these may signal neurological copper involvement requiring treatment adjustment
Monitoring Timeline
| Timeframe | What Patient Could Expect |
| Month 1 to 3 | Dose titration, monthly blood and urine monitoring, early symptom improvement |
| Month 4 to 6 | Urinary copper normalising, liver enzymes trending down, energy improving |
| Month 6 | Repeat elastography and full biochemical review |
| Month 9 to 12 | Transition planning toward zinc maintenance alongside chelation |
| Ongoing | Lifelong monitoring every three months to maintain copper balance and detect any organ changes early |
Patient Feedback
“Nobody connected the dots for months. I was just told I was stressed. When Dr. Kothari finally explained what was actually happening and showed me the test results, it made everything make sense. The treatment was gradual and I was checked regularly so I never felt like I was on my own with it. I am doing well now and my studies are back on track.”
Profile: Male, 19 years, College student, Pune
Procedure: Copper chelation and long term management for Wilson disease, Pune, January 2026
Surgeon: Dr. Ksheetij Kothari, Consultant Gastroenterologist
Disclaimer:The information shared in this content is for educational purposes only and not for promotional use.